RxDoctor Payments Data

Lindsay Hanna, NP

Family · Atascadero, CANPI 1699257907

Payments from drug & device makers

$780in general payments, 2019–2025

Across 41 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$304
  • Bayer$96
  • Novo Nordisk$89
  • Boehringer Ingelheim$66
  • AbbVie$60
  • Exact Sciences$54
  • plus $111 from 4 others

What the payments were for

  • Food & beverage$780100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$780 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$62,696
Medicare patients
214
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide17$38,823
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$38,380
JardianceEmpagliflozin38$34,806
TrulicityDulaglutide17$31,249
EliquisApixaban22$27,403
OzempicSemaglutide24$22,333
Breo ElliptaFluticasone/Vilanterol18$10,563
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$5,083
Levothyroxine Sodium130$2,268
Atorvastatin Calcium145$1,581
Albuterol Sulfate HfaAlbuterol Sulfate53$1,508
Omeprazole100$1,379
Lisinopril154$1,353
Gabapentin96$1,278
Metoprolol Succinate52$1,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$23$70,07234 claims
GSKTrelegy Ellipta, Breo Ellipta$304$48,94351 claims
Boehringer IngelheimJardiance$66$34,80638 claims
PfizerEliquis$38$27,40322 claims
Novo NordiskOzempic$89$22,33324 claims
AbbVieSynthroid$60$73021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,634 family providers in California.

Other family in Atascadero

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →